Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
December 05, 2024 08:30 ET
|
Pharma Two B Ltd.
Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s disease (PD) support P2B001 as a first line, once-daily treatment choice for...
Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting
April 05, 2022 07:30 ET
|
Pharma Two B Ltd.
REHOVOT, Israel, April 05, 2022 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...
Pharma Two B to Host a Virtual KOL Event on Successful Phase III Study Results of P2B001 in Parkinson’s Disease (PD)
January 20, 2022 07:00 ET
|
Pharma Two B Ltd.
Leading KOLs Dr. Robert Hauser and Dr. Warren Olanow will discuss the unmet medical need in early-stage PD and the uniquely favorable efficacy and safety profile of P2B001 Results demonstrate...
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease
December 15, 2021 07:30 ET
|
Pharma Two B Ltd.
Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a...
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease
December 15, 2021 07:30 ET
|
Pharma Two B Ltd.
Study successfully met its primary and key secondary endpoints, demonstrating superior efficacy of P2B001 compared to its individual components P2B001 showed comparable efficacy to a marketed...
Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea
November 18, 2021 09:00 ET
|
Pharma Two B Ltd.
Myung In Pharm to lead registration, commercialization and manufacturing of P2B001 in South Korea Myung In Pharm made a $5 million equity investment in Pharma Two B REHOVOT, Israel, Nov. ...
Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson’s Disease
September 13, 2021 08:00 ET
|
Pharma Two B Ltd.
REHOVOT, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD),...
Update -- Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors
August 23, 2021 07:00 ET
|
Pharma Two B Ltd.
REHOVOT, Israel, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today...
Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors
August 12, 2021 08:00 ET
|
Pharma Two B Ltd.
REHOVOT, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease (PD), today...
Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer
January 05, 2021 07:00 ET
|
Pharma Two B Ltd.
REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, today...